Lexeo Therapeutics, Inc. (LXEO)
2.80
-0.10
(-3.61%)
USD |
NASDAQ |
Nov 06, 10:26
Lexeo Therapeutics Net Income (Quarterly) : -25.87M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -25.87M |
| March 31, 2026 | -20.20M |
| December 31, 2025 | -20.92M |
| September 30, 2025 | -20.28M |
| June 30, 2025 | -26.10M |
| March 31, 2025 | -32.66M |
| December 31, 2024 | -25.92M |
| September 30, 2024 | -29.49M |
| June 30, 2024 | -21.24M |
| Date | Value |
|---|---|
| March 31, 2024 | -21.68M |
| December 31, 2023 | -14.19M |
| September 30, 2023 | -20.11M |
| June 30, 2023 | -13.44M |
| March 31, 2023 | -18.66M |
| December 31, 2022 | -14.58M |
| September 30, 2022 | -17.06M |
| June 30, 2022 | -15.14M |
| March 31, 2022 | -12.50M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 25.87M |
| EPS Diluted (Quarterly) | -0.3021 |
| Enterprise Value | 23.51M |
| Earnings Yield | -41.34% |
| Normalized Earnings Yield | -41.34 |